• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Corteva (CTVA) Valuation Check After Resurrect Bio Funding And Recent Share Price Momentum

    Simply Wall St·02/18/2026 09:28:06
    Listen to the news

    Corteva (CTVA) is drawing fresh attention after leading Resurrect Bio’s US$8.1 million Series A round through its Corteva Catalyst platform. The move is aimed at supporting new crop protection traits and potential commercial partnerships.

    See our latest analysis for Corteva.

    Alongside the Resurrect Bio investment and a recently completed US$569.98 million share buyback, Corteva’s 30 day share price return of 8.49% and 90 day share price return of 16.81% suggest momentum has been building, supported by a 1 year total shareholder return of 18.41%.

    If this kind of dealmaking has your attention, it could be a good moment to look at other agriculture linked opportunities through our list of 7 top copper producer stocks as a potential starting point.

    Solid recent returns, a US$82.76 price target that sits above the current US$75.55 share price, and an intrinsic value estimate implying a premium all raise the same question: is Corteva still a buy or is future growth already priced in?

    Most Popular Narrative: 7.9% Undervalued

    With Corteva closing at $75.55 against a widely followed fair value estimate of $82.05, the current setup reflects analyst expectations on growth, margins, and required returns.

    Advancements in Corteva's innovation pipeline, including premium trait launches (Vorceed, PowerCore), expansion of biological products, and gene editing, enable premium pricing, secure market share, and improve product mix, translating into higher gross margins and earnings growth.

    Read the complete narrative.

    Curious what earnings path and revenue mix could justify that higher fair value with a lower discount rate and richer future P/E multiple? The narrative leans on a very specific blend of margin expansion, steady top line growth, and capital returns that go well beyond a simple crop cycle story.

    Result: Fair Value of $82.05 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, the story could change quickly if pricing pressure in Crop Protection or tighter environmental rules begin to weigh on margins and on assumptions about long term demand.

    Find out about the key risks to this Corteva narrative.

    Another View: Premium Price Tag On Earnings

    There is a twist once you look at Corteva through its P/E. The shares trade on 42.6x earnings, compared with 15.8x for peers and 26.8x for the wider US Chemicals industry, while our fair ratio sits at 28.3x. That gap suggests you are paying a clear premium, so you need to decide whether Corteva’s story really justifies it.

    See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:CTVA P/E Ratio as at Feb 2026
    NYSE:CTVA P/E Ratio as at Feb 2026

    Next Steps

    If this mix of potential and questions around Corteva resonates with you, take a closer look now and weigh up 2 key rewards and 1 important warning sign for yourself.

    Looking for more investment ideas?

    If Corteva has sharpened your focus on quality and price, do not stop here. Broaden your watchlist with a few targeted sets of opportunities.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.